CLDX
Price
$23.78
Change
+$1.02 (+4.48%)
Updated
Jan 17 closing price
Capitalization
1.58B
44 days until earnings call
KRYS
Price
$148.39
Change
+$3.58 (+2.47%)
Updated
Jan 17 closing price
Capitalization
4.27B
44 days until earnings call
Ad is loading...

CLDX vs KRYS

Header iconCLDX vs KRYS Comparison
Open Charts CLDX vs KRYSBanner chart's image
Celldex Therapeutics
Price$23.78
Change+$1.02 (+4.48%)
Volume$854.67K
Capitalization1.58B
Krystal Biotech
Price$148.39
Change+$3.58 (+2.47%)
Volume$180.09K
Capitalization4.27B
CLDX vs KRYS Comparison Chart
Loading...
CLDX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
KRYS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CLDX vs. KRYS commentary
Jan 19, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CLDX is a Hold and KRYS is a Hold.

Ad is loading...
COMPARISON
Comparison
Jan 19, 2025
Stock price -- (CLDX: $23.78 vs. KRYS: $148.39)
Brand notoriety: CLDX and KRYS are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CLDX: 81% vs. KRYS: 66%
Market capitalization -- CLDX: $1.58B vs. KRYS: $4.27B
CLDX [@Biotechnology] is valued at $1.58B. KRYS’s [@Biotechnology] market capitalization is $4.27B. The market cap for tickers in the [@Biotechnology] industry ranges from $368.92B to $0. The average market capitalization across the [@Biotechnology] industry is $2.37B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CLDX’s FA Score shows that 0 FA rating(s) are green whileKRYS’s FA Score has 1 green FA rating(s).

  • CLDX’s FA Score: 0 green, 5 red.
  • KRYS’s FA Score: 1 green, 4 red.
According to our system of comparison, both CLDX and KRYS are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CLDX’s TA Score shows that 4 TA indicator(s) are bullish while KRYS’s TA Score has 4 bullish TA indicator(s).

  • CLDX’s TA Score: 4 bullish, 3 bearish.
  • KRYS’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, CLDX is a better buy in the short-term than KRYS.

Price Growth

CLDX (@Biotechnology) experienced а -2.34% price change this week, while KRYS (@Biotechnology) price change was -2.96% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -1.44%. For the same industry, the average monthly price growth was +2.66%, and the average quarterly price growth was -1.92%.

Reported Earning Dates

CLDX is expected to report earnings on May 13, 2025.

KRYS is expected to report earnings on May 12, 2025.

Industries' Descriptions

@Biotechnology (-1.44% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
KRYS($4.27B) has a higher market cap than CLDX($1.58B). KRYS YTD gains are higher at: -5.279 vs. CLDX (-5.896). KRYS has higher annual earnings (EBITDA): 181M vs. CLDX (-171.06M). CLDX has more cash in the bank: 756M vs. KRYS (588M). CLDX has less debt than KRYS: CLDX (3.09M) vs KRYS (7.48M). KRYS has higher revenues than CLDX: KRYS (242M) vs CLDX (9.98M).
CLDXKRYSCLDX / KRYS
Capitalization1.58B4.27B37%
EBITDA-171.06M181M-95%
Gain YTD-5.896-5.279112%
P/E RatioN/A83.37-
Revenue9.98M242M4%
Total Cash756M588M129%
Total Debt3.09M7.48M41%
FUNDAMENTALS RATINGS
CLDX vs KRYS: Fundamental Ratings
CLDX
KRYS
OUTLOOK RATING
1..100
5468
VALUATION
overvalued / fair valued / undervalued
1..100
57
Fair valued
81
Overvalued
PROFIT vs RISK RATING
1..100
4825
SMR RATING
1..100
9680
PRICE GROWTH RATING
1..100
8964
P/E GROWTH RATING
1..100
10099
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

CLDX's Valuation (57) in the Biotechnology industry is in the same range as KRYS (81) in the Pharmaceuticals Major industry. This means that CLDX’s stock grew similarly to KRYS’s over the last 12 months.

KRYS's Profit vs Risk Rating (25) in the Pharmaceuticals Major industry is in the same range as CLDX (48) in the Biotechnology industry. This means that KRYS’s stock grew similarly to CLDX’s over the last 12 months.

KRYS's SMR Rating (80) in the Pharmaceuticals Major industry is in the same range as CLDX (96) in the Biotechnology industry. This means that KRYS’s stock grew similarly to CLDX’s over the last 12 months.

KRYS's Price Growth Rating (64) in the Pharmaceuticals Major industry is in the same range as CLDX (89) in the Biotechnology industry. This means that KRYS’s stock grew similarly to CLDX’s over the last 12 months.

KRYS's P/E Growth Rating (99) in the Pharmaceuticals Major industry is in the same range as CLDX (100) in the Biotechnology industry. This means that KRYS’s stock grew similarly to CLDX’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CLDXKRYS
RSI
ODDS (%)
N/A
Bullish Trend 11 days ago
79%
Stochastic
ODDS (%)
Bearish Trend 11 days ago
75%
Bullish Trend 11 days ago
74%
Momentum
ODDS (%)
Bullish Trend 11 days ago
83%
Bearish Trend 11 days ago
81%
MACD
ODDS (%)
Bullish Trend 11 days ago
85%
Bullish Trend 11 days ago
81%
TrendWeek
ODDS (%)
Bullish Trend 11 days ago
83%
Bullish Trend 11 days ago
77%
TrendMonth
ODDS (%)
Bullish Trend 11 days ago
81%
Bearish Trend 11 days ago
75%
Advances
ODDS (%)
Bullish Trend 16 days ago
83%
Bullish Trend about 1 month ago
76%
Declines
ODDS (%)
Bearish Trend 20 days ago
79%
Bearish Trend 17 days ago
76%
BollingerBands
ODDS (%)
Bearish Trend 11 days ago
90%
N/A
Aroon
ODDS (%)
N/A
Bearish Trend 11 days ago
81%
View a ticker or compare two or three
Ad is loading...
CLDX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
KRYS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
MICHX9.040.14
+1.57%
Matthews China Small Companies Instl
JFRNX58.420.62
+1.07%
Janus Henderson Forty N
FFGIX18.650.17
+0.92%
Fidelity Advisor Global Commodity Stk I
MSMJX30.440.13
+0.43%
Invesco Main Street Mid Cap R5
DRSVX18.310.05
+0.27%
Foundry Partnersl Sm Cp Val Inv

CLDX and

Correlation & Price change

A.I.dvisor indicates that over the last year, CLDX has been loosely correlated with KRYS. These tickers have moved in lockstep 56% of the time. This A.I.-generated data suggests there is some statistical probability that if CLDX jumps, then KRYS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CLDX
1D Price
Change %
CLDX100%
+4.48%
KRYS - CLDX
56%
Loosely correlated
+2.47%
ALT - CLDX
45%
Loosely correlated
+2.24%
AXON - CLDX
43%
Loosely correlated
+1.37%
NTLA - CLDX
42%
Loosely correlated
+0.85%
BEAM - CLDX
42%
Loosely correlated
+0.17%
More

KRYS and

Correlation & Price change

A.I.dvisor indicates that over the last year, KRYS has been loosely correlated with CLDX. These tickers have moved in lockstep 57% of the time. This A.I.-generated data suggests there is some statistical probability that if KRYS jumps, then CLDX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To KRYS
1D Price
Change %
KRYS100%
+2.47%
CLDX - KRYS
57%
Loosely correlated
+4.48%
BEAM - KRYS
47%
Loosely correlated
+0.17%
ZLDPF - KRYS
45%
Loosely correlated
+1.17%
ALT - KRYS
45%
Loosely correlated
+2.24%
VCYT - KRYS
44%
Loosely correlated
-1.27%
More